Glucocorticoids remain the cornerstone of anti-inflammatory therapy for ARDS, and they work mainly by inhibiting the NF-κB signaling pathway, thereby reducing the production of key cytokines such as IL-6 and TNF-α [110,111]. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.